Prophylaxis and treatment of hepatitis B infection in the setting of liver transplantation

Delia D’Avola and José Ignacio Herrero

Liver Unit. Clínica Universitaria. Pamplona, Navarra. Spain and centro de Investigación Biomédica en Red de enfermedades hepáticas y digestivas (CIBERehd)

ABSTRACT

Without any treatment, the prognosis of hepatitis B in liver transplant recipients is very poor. So, antiviral prophylaxis is very important in patients with hepatitis B who undergo liver transplantation. Before liver transplantation, a suppression of viral replication has to be achieved by nucleos(t)ide analogs. Drugs used in the prophylaxis of post-transplant hepatitis B include immunoglobulin against HBV and nucleos(t)ide analogs. Prophylaxis against graft infection must be based on the individual risk of recurrence. When prophylactic measures have failed and graft infection has occurred, treatment of recurrent hepatitis B may be based on the resistance profile of the virus and previous antiviral exposure. Finally, lamivudine seems to be very effective in the prevention of de novo hepatitis B in patients transplanted with a graft from an anti-HBc positive donor.

Key words: Hepatitis B. Prophylaxis. Liver transplantation.

INTRODUCTION

Hepatitis B virus (HBV)-related liver cirrhosis accounts for 5-10% of liver transplantations performed in Spain (1). Until latest ‘80s prognosis of transplant recipients for HBV-related cirrhosis was very poor, and graft loss due to recurrent HBV infection was the rule. In the last two decades, the availability of hyperimmune immunoglobulin and oral antiviral agents, have definitely changed the prognosis of liver transplantation for HBV-related diseases. Currently, 5-years survival rate is around 85%, compared to 45% at 3 years before the immunoglobulin era (1,2).

Hepatitis B recurrence still plays an important role in determining survival after liver transplantation, and in some series it has been suggested that recurrent hepatitis B may have a role in promoting recurrence of liver cancer (3) and lymphoproliferative disorders after transplantation (4). Antiviral treatment, before and after liver transplantation, markedly reduces the risk of hepatitis B recurrence. High levels of HBV-DNA and presence of HBV e antigen (HBeAg) at the time of liver transplantation, as well as HBV-related liver cirrhosis are the most important predictors of hepatitis B recurrence. Conversely, acute liver failure and HBV-HDV coinfection have been regarded as protective factors.

In the early ’90, a multicenter European study showed a 32% recurrence rate among HBV-hepatitis D virus (HDV) coinfected patients compared to 53% in patients with HBV infection alone (6). The protective role of HDV infection has been shown only in liver cirrhosis, but not in acute hepatitis B, and it is supposed to be related to the inhibition of HBV replication (7).
In the setting of liver transplantation, three different clinical situations have to be distinguished: a) treatment of HBV infection during waiting list; b) prophylaxis of hepatitis B recurrence after liver transplantation; and c) treatment of recurrent hepatitis B when prophylactic measures have failed. Moreover, de novo hepatitis B can occur when liver from donors with antibodies against the HBV core antigen (anti-HBc) are transplanted. This donors account for 10-12% of the livers transplanted in Spain.

TREATMENT OF HEPATITIS B PRIOR TO LIVER TRANSPLANTATION

The availability of oral antiviral drugs, in the latest decades, has definitely changed the management of HBV-liver cirrhosis. Lamivudine, the first oral antiviral agent against HBV, is safe and well tolerated even in patients with decompensated liver cirrhosis (8). Patients with decompensated HBV-liver cirrhosis may benefit of lamivudine treatment: their liver function may improve, complications of liver cirrhosis may resolve and, in some cases, liver transplantation is not longer needed (9-11). Hyper-immune immunoglobulin and nucleos(t)ide analogs, administered after liver transplantation, dramatically reduce the risk of hepatitis B recurrence; however, patients with a high HBV-viral load at the time of liver transplantation have a high risk of recurrent hepatitis, despite prophylaxis (6,12).

For this reason, the main national and international hepatology societies (Asociación Española para el Estudio del Hígado, AEEH, American Association for the Study of Liver Diseases, AASLD, and European Association for the Study of the Liver, EASL) recommend the aggressive treatment of HBV infection before liver transplantation (13-15).

The goal of antiviral therapy during waiting list is double: first, to minimize viral replication prior to transplantation (ideally achieving a total suppression of viral replication), and secondly, to improve liver function in order to reduce mortality during waiting list (16). In the setting of liver transplantation, as well as in other clinical situations, the choice of antiviral drugs depends on the severity of liver cirrhosis. Patients with chronic hepatitis or compensated liver cirrhosis, that usually have hepatocellular carcinoma, should be treated equally to patients not listed for liver transplantation. Highly potent antiviral agents (e.g. entecavir, tenofovir or telbivudine) are recommended as monotherapy or as combination therapy, according to the presence of comorbidities and the resistance profile of HBV. However, safety and efficacy data of these new antiviral agents are not yet available. As a consequence, lamivudine and adefovir are the only two agents approved for the treatment of decompensated liver cirrhosis and lamivudine is the most used.

A major concern of long-term lamivudine therapy is the high resistance rate that reaches 10-20% at 1 year and is above 60% after 4 years of treatment. Although the long-term resistance rate should not be an issue in a waiting list setting, a 10% of lamivudine-resistance rate has been reported among a series of wait-listed patients, because of the emergence of resistant strains after 1 year of treatment (9,11,17). In addition, the duration of waiting time is not predictable and the HBV reactivation in cirrhotics could result in high mortality and morbidity (18). So, although it is approved for HBV decompensated liver cirrhosis, lamivudine alone is not longer recommended in this setting and its association with adefovir is strongly suggested (14).

Adefovir is effective for lamivudine-resistant strains, resulting in the suppression of viral replication. Adefovir has been successfully used in patients with advanced cirrhosis and lamivudine-resistant hepatitis B, leading to an improvement of liver function as shown by the reduction of Child-Pugh score (19). The main concern about adefovir treatment is the risk or kidney dysfunction. In addition, compared to other antiviral agents, the time to achieve a complete viral suppression with adefovir could be longer (20,21).

New oral antiviral agents seem a promising possibility for the future in the treatment of wait-listed patients, however they are not already approved for the use in decompensated liver cirrhosis. Among these, entecavir is highly and rapidly effective, and it could be used when a rapid viral suppression is required or in patients showing nephrotoxicity related to adefovir. It has been recently showed highly effective on inhibiting viral replication among cirrhotic patients. However its safety among patients with poor liver function remain uncertain, because of some reports of lactic acidosis in severely decompensated liver disease (MELD > 18) (22,23).

Compared to entecavir, tenofovir is more effective among lamivudine-resistant strains, and it has a better therapeutic index in patients with impaired renal function, compared to adefovir (24).

Because of their efficacy and safety, entecavir and tenofovir, used as monotherapy or in combination, are considered as the first choice agents, in patients with chronic hepatitis or compensated liver cirrhosis listed for liver transplantation.

Finally, telbivudine has shown powerful antiviral activity, with lower resistance rates compared to lamivudine. One of the major advantages of telbivudine is its activity against adefovir-resistant strains. It is approved for use in compensated liver disease but, safety data in patients with decompensated liver disease are not available to date (21).

While treatment of chronic liver disease during waiting list is universally accepted, there is not a general consensus about treatment of patients with acute liver failure who are listed for liver transplantation. As mentioned before, the risk of recurrent hepatitis B in patients transplanted for acute hepatitis B is lower than that observed in patients transplanted for liver cirrhosis. However some
recent reports suggest a possible role of antiviral agents in improving the prognosis of acute liver failure and its use in this setting is currently debated (6,25,26).

Summarizing, in patients in waiting list for liver transplantation, the choice of antiviral agent should take into account the degree of liver dysfunction. For patients with compensated liver disease (i.e., compensated liver cirrhosis or chronic hepatitis) a high potency antiviral agent, such as entecavir, tenofovir and telbivudine, is strongly recommended, according to comorbidities and the resistance profile.

In patients with decompensated liver cirrhosis, the association of lamivudine and adefovir is considered the first line therapy, at least in naive patients not requiring an immediate viral suppression. Newer antiviral agents, not already approved for decompensated liver cirrhosis, are an attractive option for patients listed for liver transplantation, especially when a rapid viral suppression is needed, in presence of resistance to lamivudine or adefovir or in patients with contraindications to these two agents.

PROPHYLAXIS OF HEPATITIS B RECURRENCE AFTER LIVER TRANSPLANTATION

Ideally, the treatment of patients on the waiting list achieves a complete suppression of viral replication at the time of liver transplantation. Pre-transplant treatment reduces the recurrence rate in the graft (6,12). Nevertheless, to prevent hepatitis B recurrence, prophylactic measures have to be taken immediately after liver transplantation.

Hyperimmune immunoglobulin against HBV has been the first effective treatment in the prophylaxis of hepatitis B recurrence after liver transplantation. Nowadays, immunoglobulin are the most used drug in this clinical setting; however there is no a general agreement on dose, administration route and treatment schedules that have to be used (27,28).

Unfortunately, the use of immunoglobulin alone, even with long-term administration, results in 36 and 56% of recurrence rate at 3 and 5-years after liver transplantation, at least among patients with high recurrence risk (i.e. patients with positive HBV-DNA at the time of transplantation, or in patients with HBeAg) (6).

The efficacy of lamivudine as monotherapy is similar to that of immunoglobulin alone, leading to a 40-50% of recurrence at 3-years after transplantation (29,30). The combination of both has emerged as the most effective prophylactic strategy in HBV transplant recipients, resulting in a 3-years recurrence rate of 0-10% in the majority of published series (31-33).

The major concerns with the immunoglobulin therapy are the high cost and the administration route (parenteral), especially when considering the need of long term prophylaxis. Consequently, in the last 10 years, alternative therapeutic regimens with low dose immunoglobulin or using different antiviral agents have been evaluated.

In the attempt to lowering costs without decreasing the efficacy, combination of lamivudine with intramuscular immunoglobulin and/or therapeutic protocols including low dose immunoglobulin regimens (400-800 UI/months) have been investigated (34,35). Similarly, other investigators have explored individualized immunoglobulin dosing, according to anti-hepatitis B surface (anti-HBs) titers. This strategy could reduce the pharmacy cost of antiviral prophylaxis but increases the complexity of the follow-up of the patient and the work load for nurses and physicians.

Currently the global recurrence rate with the different proposed therapeutic protocols, including the association of nucleos(t)ide analogs and immunoglobulin, is reported around 0 and 10%, varying accordingly to the different risk factors at the time of liver transplantation (34,36-38). When considering patients with lamivudine-resistant hepatitis B, prophylactic treatment with immunoglobulin and lamivudine are less effective, resulting in recurrence rates of 15-22% (39). In these patients the use of a different antiviral agent (according to the resistance profile) in combination with immunoglobulin, should be considered, and the treatment choice has to regard the resistance profile. In this clinical setting, adefovir is probably the most explored antiviral agent. When it is used in patients with lamivudine resistance, the recurrence rate is 10% or lower (19).

The withdrawal of immunoglobulin, while long term oral antiviral treatment, is a safe therapeutic strategy, at least in patients with low risk of recurrence or in patients without recurrence after a prolonged treatment with combined lamivudine and immunoglobulin (40-45). In low-risk patients, who were HBV-negative at the time of liver transplantation, and received long term prophylaxis with lamivudine, the recurrence rates were similar when they received immunoglobulins for a short period of weeks or indefinitely (40). The effect of early withdrawal of immunoglobulin, while on long-term lamivudine prophylaxis, leads to 8-18% recurrence. Compliance with oral antivirals is critical for long-term outcome of this strategy (41).

Among low-risk patients after 12 months of immunoglobulin prophylaxis, other antiviral agents, such as adefovir, have been investigated as an alternative to long-term immunoglobulin (36). Similarly, newer high potency antivirals with a lower long-term resistance rate, are a promising option in an attempt to reduce the duration of immunoglobulin prophylaxis or to use low-dose regimens (46).

Active immunization with recombinant HBV vaccines has been investigated as an alternative to long-term immunoglobulin in low-risk patients (47-49). Most patients included in these studies had undetectable HBV replication and HBeAg-negative at the time of liver transplantation, did not show recurrent hepatitis B after the withdrawal of immunoglobulin prophylaxis and had been transplanted many years before, so they required a medi-
LIVER RECIPIENTS FROM ANTI-HBC-POSITIVE DONORS

Prevalence of antibodies against the HBV core antigen (anti-HBc) among liver donors varies according to the prevalence of hepatitis B in different geographic areas. It reaches 30-80% of liver donors in Asia and 10% in western countries (10-12% in Spain) (1,51, 52).

Anti-HBc-positivity of the donor is the main risk factor for de novo hepatitis B in liver transplant recipients. In older reports, patients who receive a graft from an anti-HBc-positive donor have shown a poor survival, but in the majority of recent series, survival among patients receiving an anti-HBc-positive graft is comparable to that of recipients of anti-HBc-negative liver (1,53,54). Serological status of the receptor and the viral load in the graft, strongly determine the risk of de novo hepatitis B among recipients of antiHBc-positive graft. Without any prophylaxis, the risk of de novo hepatitis B in naive patients receiving anti-HBc-positive graft is 40% compared to 10% in recipients with antibodies against HBV surface antigen (anti-HBs). This risk is similar (13%) in recipients who only have anti-HBc, and is very low (2%) in patients with both anti-HBc and anti-HBs (55) (Table I).

Among the several prophylactic regimens for the prevention of de novo hepatitis B in anti-HBc-positive graft recipients, long-term lamivudine is the most used. Depending on the serological status of the recipient, patients receiving prophylaxis with lamivudine have a risk of developing de novo hepatitis B below 4% (53, 56,57). In some centers lamivudine is combined with immunoglobulin...
lin, however a real advantage of this strategy compared to lamivudine alone has never been shown (58,59).

Immunoglobulin prophylaxis is less effective than lamivudine, leading to a 10% of de novo hepatitis B among anti-HBc-positive recipients and above 20% among seronegative patients (60-62).

Lamivudine prophylaxis is almost universally accepted and is strongly recommended in all liver recipients regardless their serological status, even in anti-HBc-positive recipients. According to the low rate of de novo hepatitis in anti-HBc-positive recipients, prophylaxis could be unnecessary in them.

TREATMENT OF HEPATITIS B IN LIVER TRANSPLANTATION RECIPIENTS

At the present time, recurrence of hepatitis B occurs in less than 20% of liver recipients 4 years after liver transplantation (2). Among transplanted patients, HBV infection (de novo hepatitis or recurrent) could show an aggressive clinical course, characterized by a marked inflammation and rapidly progressive fibrosis. Cholestatic fibrosing hepatitis is an exclusive hepatitis B pattern of immunosuppressed patients. It is characterized by lobular disarray, cholangiolar proliferation, severe fibrosis and mild inflammation (63-65). Treatment of hepatitis B among liver recipients is based on the same principles as in not transplanted patients. However, in presence of an aggressive clinical course, when a rapid suppression of viral replication is required, high potency antiviral agents should be used (66). As in non-transplanted patients, the choice of treatment must be based on the previous antiviral treatments, the resistance profile and the presence of comorbidities, especially renal insufficiency.

Until the early 2000, the most used antiviral agents against HBV have been interferon and lamivudine. Nowadays, because of its limited efficacy and the risk of graft rejection, interferon is not longer used in this clinical setting. Similarly, due to the need of long-term treatment and considering that lamivudine resistance rate raises the 70% after 4-5 years of treatment, lamivudine monotherapy is currently abandoned (67). The availability of adefovir has changed the clinical course of lamivudine-resistant recurrent hepatitis B, and it is effective and safe among liver transplantation recipients (19,68,69). However, adefovir treatment could lead to the emergence of resistant strains or to incomplete suppression of viral replication; moreover it is potentially nephrotoxic and its dosage must be adjusted in patients with impaired renal function.

Tenofovir is effective against lamivudine-resistant strains and it is safe in the setting of liver transplantation. Due to its good therapeutic index and the lower resistance rate compared to adefovir, it could be a valuable therapeutic option at least for patients with kidney dysfunction (70,71). Telbivudine, has a possible role in the presence of adefovir resistant strains, however its safety and efficacy have not been proven in liver recipients. Entecavir is highly effective in patients naïve for nucleos(t)ide analogs. However its antiviral activity is limited among patients with lamivudine-resistant hepatitis B, in whom a genotypic resistance to entecavir has been found around 15% after 2 years of treatment (72). As the other newer antiviral agents, entecavir is an attractive option for liver receptors; however safety and efficacy data in this clinical setting are needed.

CONCLUSIONS

Antiviral treatment is strongly recommended among all candidates for liver transplantation with active hepatitis B infection. The ideal antiviral agent should have a minimal risk of resistance and achieve a rapid viral suppression. The goal of the treatment is to achieve a complete suppression of viral replication at the time of liver transplantation, in order to reduce the risk of recurrence after transplantation. In Spain, lamivudine and adefovir are the only two antiviral agents approved for patients with decompensated liver cirrhosis; however, in specific situations, the use of other agents, such as entecavir, adefovir and telbivudine, should be considered accordingly to the presence of comorbidities or previous antiviral resistance.

Independently of the serological status of the recipients, after transplantation, prophylaxis should be given without delay. Immunoglobulin and one or two nucleos(t)ide analogs selected considering the virological status should be given. When prophylaxis has failed, hepatitis B recurrence has to be rapidly treated, according to the resistance profile and comorbidities, as in non-transplanted patients. Finally all HBsAg-negative patients receiving an HBCAb-positive graft have to receive long-term prophylaxis with lamivudine.

REFERENCES


70. Lilly L, Therapondos G, Mason AL, Kelly W, Burak W. Tenofovir is effective in suppressing HBV replication in liver transplant recipients with nucleos(t)ide resistant recurrent disease. Hepatology 2008; 48:574A.
